$30M in Hand, Ipierian Steers ‘True North’
Armed with a $30 million financing, privately held Ipierian Inc. took the bold move of launching spinout True North Therapeutics, with a portion of the funds serving as the newco’s Series A. Nancy Stagliano, who serves as CEO of both companies, said the decision to split was driven by advancements in Ipierian’s two monoclonal antibody (mAb) programs, targeting the tau protein and complement pathways.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter